melatonin has been researched along with Hypergonadotropic Hypogonadism in 28 studies
Excerpt | Relevance | Reference |
---|---|---|
"The endocrine system of aging males reveals changes of more or less unknown significance for estrogens, dehydroepiandrosterone (DHEA), melatonin and growth hormone." | 8.82 | [Hormone therapy in the aging male. Estrogen, DHEA, melatonin, somatotropin]. ( Kliesch, S, 2004) |
"Elevated nocturnal melatonin is found in women with idiopathic hypogonadotropic hypogonadism (IHH), but it is not known whether this is implicated in the etiology of their GnRH deficiency." | 7.70 | Elevated nocturnal melatonin is a consequence of gonadotropin-releasing hormone deficiency in women with hypothalamic amenorrhea. ( Di, WL; Djahanbakhch, O; Kadva, A; Monson, J; Silman, R, 1998) |
"Increased melatonin secretion observed in male patients with congenital isolated hypogonadotropic hypogonadism and its normalization during testosterone treatment had suggested that melatonin and the reproductive hormones are inter-related." | 7.70 | Melatonin hypersecretion in male patients with adult-onset idiopathic hypogonadotropic hypogonadism. ( Ishai, A; Lavie, P; Luboshitzky, R; Shen-Orr, Z, 2000) |
"It has previously been shown that increased nocturnal melatonin (MT) secretion exists in male patients with hypogonadotropic hypogonadism." | 7.69 | Daytime plasma melatonin levels in male hypogonadism. ( Beyhan, Z; Bingol, N; Bolu, E; Bulur, M; Corakci, A; Gundogan, MA; Ozata, M, 1996) |
"The endocrine system of aging males reveals changes of more or less unknown significance for estrogens, dehydroepiandrosterone (DHEA), melatonin and growth hormone." | 4.82 | [Hormone therapy in the aging male. Estrogen, DHEA, melatonin, somatotropin]. ( Kliesch, S, 2004) |
"Elevated nocturnal melatonin is found in women with idiopathic hypogonadotropic hypogonadism (IHH), but it is not known whether this is implicated in the etiology of their GnRH deficiency." | 3.70 | Elevated nocturnal melatonin is a consequence of gonadotropin-releasing hormone deficiency in women with hypothalamic amenorrhea. ( Di, WL; Djahanbakhch, O; Kadva, A; Monson, J; Silman, R, 1998) |
"Increased melatonin secretion observed in male patients with congenital isolated hypogonadotropic hypogonadism and its normalization during testosterone treatment had suggested that melatonin and the reproductive hormones are inter-related." | 3.70 | Melatonin hypersecretion in male patients with adult-onset idiopathic hypogonadotropic hypogonadism. ( Ishai, A; Lavie, P; Luboshitzky, R; Shen-Orr, Z, 2000) |
"It has previously been shown that increased nocturnal melatonin (MT) secretion exists in male patients with hypogonadotropic hypogonadism." | 3.69 | Daytime plasma melatonin levels in male hypogonadism. ( Beyhan, Z; Bingol, N; Bolu, E; Bulur, M; Corakci, A; Gundogan, MA; Ozata, M, 1996) |
"To clarify whether disorders of gonadotropin releasing hormone (GnRH) deficiency are associated with altered melatonin and pituitary hormones secretory patterns, we studied male patients with hypogonadotropic hypogonadism (IGD; n = 6), delayed puberty (DP; n = 7) and age-matched pubertal controls (n = 7)." | 3.69 | Nocturnal secretory patterns of melatonin, luteinizing hormone, prolactin and cortisol in male patients with gonadotropin-releasing hormone deficiency. ( Herer, P; Lavi, S; Lavie, P; Luboshitzky, R; Thuma, I, 1996) |
"Circadian serum melatonin profiles were studied in six men with primary hypogonadism before and during testosterone substitution and compared with an age-matched control group (n = 6)." | 3.69 | Melatonin concentration before and during testosterone replacement in primary hypogonadic men. ( de Leiva, A; García Patterson, A; Puig-Domingo, M; Rajmil, O; Schwarzstein, D; Tortosa, F; Viader, M, 1997) |
"Pretreatment melatonin levels in IGD were greater than those in age-matched pubertal controls while in KS, melatonin levels were lower than values in controls." | 2.68 | Abnormal melatonin secretion in hypogonadal men: the effect of testosterone treatment. ( Herer, P; Lavi, S; Lavie, P; Luboshitzky, R; Wagner, O, 1997) |
"Melatonin is a hormone mainly secreted by the pineal gland during the dark phase of the light-dark cycle." | 2.41 | [Melatonin. I. Physiology of its secretion]. ( Bruls, E; Crasson, M; Legros, JJ, 2000) |
"Male patients with hypogonadotropic hypogonadism (IGD, n = 6), constitutional delayed puberty (DP, n = 6), and Klinefelter's syndrome (KS, n = 5) before and during testosterone replacement therapy were studied." | 1.30 | The association between melatonin and sleep stages in normal adults and hypogonadal men. ( Lavi, S; Lavie, P; Luboshitzky, R, 1999) |
"Melatonin levels were equal in patients and controls when T and E2 levels were well matched." | 1.29 | Testosterone treatment alters melatonin concentrations in male patients with gonadotropin-releasing hormone deficiency. ( Lavi, S; Lavie, P; Luboshitzky, R; Thuma, I, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (10.71) | 18.7374 |
1990's | 18 (64.29) | 18.2507 |
2000's | 5 (17.86) | 29.6817 |
2010's | 2 (7.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, C | 1 |
Ling, MY | 1 |
Lin, FH | 1 |
Xu, L | 1 |
Lv, ZM | 1 |
Smith, RP | 1 |
Coward, RM | 1 |
Kovac, JR | 1 |
Lipshultz, LI | 1 |
Cuzin, B | 1 |
Giuliano, F | 1 |
Jamin, Ch | 1 |
Legros, JJ | 2 |
Lejeune, H | 1 |
Rigot, JM | 1 |
Roger, M | 1 |
Kliesch, S | 1 |
Kumanov, P | 1 |
Tomova, A | 1 |
Isidori, A | 1 |
Nordio, M | 1 |
Luboshitzky, R | 8 |
Lavi, S | 6 |
Thuma, I | 3 |
Lavie, P | 9 |
Nir, I | 1 |
Schmidt, U | 1 |
Zilber, N | 1 |
Ozata, M | 2 |
Bulur, M | 1 |
Bingol, N | 1 |
Beyhan, Z | 2 |
Corakci, A | 1 |
Bolu, E | 1 |
Gundogan, MA | 1 |
Herer, P | 4 |
Wagner, O | 2 |
Luboshitsky, R | 1 |
Walker, AB | 1 |
English, J | 1 |
Arendt, J | 2 |
MacFarlane, IA | 1 |
Rajmil, O | 1 |
Puig-Domingo, M | 2 |
Tortosa, F | 1 |
Viader, M | 1 |
García Patterson, A | 1 |
Schwarzstein, D | 1 |
de Leiva, A | 2 |
Leibenluft, E | 1 |
Schmidt, PJ | 1 |
Turner, EH | 1 |
Danaceau, MA | 1 |
Ashman, SB | 1 |
Wehr, TA | 1 |
Rubinow, DR | 1 |
Kadva, A | 1 |
Djahanbakhch, O | 1 |
Monson, J | 1 |
Di, WL | 1 |
Silman, R | 1 |
Manber, R | 1 |
Armitage, R | 1 |
Shen-Orr, Z | 1 |
Ishai, A | 1 |
Bruls, E | 1 |
Crasson, M | 1 |
Webb, SM | 1 |
Serrano, J | 1 |
Peinado, MA | 1 |
Corcoy, R | 1 |
Ruscalleda, J | 1 |
Reiter, RJ | 1 |
Utiger, RD | 1 |
Labib, MH | 1 |
Bojkowski, C | 1 |
Hanson, S | 1 |
Marks, V | 1 |
Grishchenko, VI | 1 |
Zubkov, GV | 1 |
Berg, GR | 1 |
Klein, DC | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Chronobiologic Effects of Gonadal Steroid Manipulations in Volunteer Subjects[NCT00001285] | 73 participants | Observational | 1991-08-31 | Completed | |||
A Mechanistic Examination of Continuous Cycle Oral Contractive Administration in Binge Eating[NCT04278755] | Phase 2 | 8 participants (Actual) | Interventional | 2020-09-24 | Terminated (stopped due to Halted prematurely due to COVID-19-related enrollment challenges.) | ||
Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model[NCT04051320] | Phase 2 | 23 participants (Actual) | Interventional | 2020-01-02 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Behavioral Inhibition/Behavioral Activation questionnaire will be used to assess behavioural inhibition (BI). The minimum score on the BI subscale is 7, maximum 28. Greater scores indicate greater BI. Change is defined as the average change in BI from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | score on a scale (Mean) |
---|---|
Continuous OC | 1.43 |
"Binge eating will be measured using the 8-item binge eating subscale of the Eating Pathology Symptoms Inventory (EPSI), which measures features of binge eating (e.g., consumption of large quantities of food, mindless eating) on a 5-point Likert scale from never to very often. The EPSI scale is designed to assess behavior over the past 28 days. Items are summed for a scale score ranging from 0-32. Higher scores indicate more frequent experiences with binge eating behavior. Change is defined as the average change in the binge eating scale score from pre-intervention to intervention." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | score on a scale (Mean) |
---|---|
Continuous OC | -6.60 |
The Monetary Choice Questionnaire will be used to measure delay discounting. Participants will be asked to make a series of hypothetical choices between small, sooner (impulsive) vs. larger, later (self controlled) hypothetical monetary outcomes. k is a hyperbolic function with larger k values indicating more valuation of a larger delayed reward and smaller values indicating preference for more immediate, smaller rewards (more impulsivity). k can range from 0 to .25 with scores of .25 indicating complete valuation of the immediate reward and 0 indicating complete valuation of the larger, delayed reward. Change is defined as the average change in k from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | k value (Mean) |
---|---|
Continuous OC | .01 |
"Nucleus Accumbens (NAcc) reactivity to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | percentage signal change (Mean) |
---|---|
Continuous OC | .0423 |
"Prefrontal cortex reactivity to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | percentage signal change (Mean) |
---|---|
Continuous OC | .01 |
Sensitivity to Punishment/Sensitivity to Reward Questionnaire will be used to measure reward sensitivity. The reward sensitivity subscale will be used, which is rated on a true/false scale with scores ranging 0-24. Higher scores indicate more sensitivity to reward. Change is defined as the average change in reward sensitivity from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | score on a scale (Mean) |
---|---|
Continuous OC | 1.60 |
Binge eating frequency is based on a weekly diary of self-reported binge eating frequency. Participants were asked how many times during the past week they had a binge eating episode. Scores can range from 0 to infinity as frequency is self-reported as the number of binge eating episodes in the previous week. Higher scores indicate more episodes of binge eating. Change is defined as the average change in self-reported binge eating frequency from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | episodes/week (Mean) |
---|---|
Continuous OC | -0.43 |
"Dorsal striatum reactivity (defined as caudate signal intensity and putamen signal intensity) to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | percentage signal change (Mean) | |
---|---|---|
Caudate | Putamen | |
Continuous OC | -.012 | .02 |
"This outcome measure determines the degree of irritability and reactive aggression in HS+ during hormone addback and its relationship to the target population. Irritability will be defined as score on the IDAS Ill Temper Scale. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~The Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to ac" (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | 0.18 |
Hormone Insensitive Women (HS-) | 0.03 |
"This outcome measure determines the degree of subcortical (amygdala, caudate, putamen, and nucleus accumbens) activation in HS+ during hormone addback and it's relationship to the target population. The activation in amygdala and ventral striatum (caudate, putamen, nucleus accumbens) regions of interest (ROIs) will be assessed during the Affective Posner Task.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | 0.47 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill Temper (i.e., irritability) Scale and threat attention bias. (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | -0.35 |
Hormone Insensitive Women (HS-) | 0.11 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Mean) |
---|---|
Hormone Sensitive Women (HS+) | -0.13 |
Hormone Insensitive Women (HS-) | 0.49 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | -0.57 |
Hormone Insensitive Women (HS-) | -0.08 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | -0.009866667 | -0.086876444 |
Hormone Sensitive Women (HS+) | 0.005316917 | -0.047401917 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0077258 | -0.049988 |
Hormone Sensitive Women (HS+) | -0.043943333 | 0.059099917 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0691907 | -0.072512 |
Hormone Sensitive Women (HS+) | -0.028451818 | 0.031632727 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0383029 | -0.021029 |
Hormone Sensitive Women (HS+) | -0.001223462 | 0.048155385 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.037334 | -0.15643 |
Hormone Sensitive Women (HS+) | -0.04544 | 0.022654 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.061407 | 0.0058011 |
Hormone Sensitive Women (HS+) | -0.069919077 | 0.045146154 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.052685333 | -0.006394444 |
Hormone Sensitive Women (HS+) | 0.044384167 | -0.005181667 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.002542222 | -0.080736333 |
Hormone Sensitive Women (HS+) | -0.007560692 | 0.036225385 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | arbitrary units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0213 | 0.00111 |
Hormone Sensitive Women (HS+) | 0.0247 | -0.0192 |
"This outcome measure determines the extent to which HS+ is characterized by reactive aggression during hormone addback relative to baseline in the target population. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to accrue money or press another button to subtract money from a (fictional) partner at no direct gain to themselves. Frustration is induced by periodic subtractions of their own money, which is attributed to the partner." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Number of subtraction responses (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 129.20 | 54.90 |
Hormone Sensitive Women (HS+) | 103.08 | 34.62 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) Blood-oxygen-level-dependent (BOLD) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | arbitrary units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0533 | 0.00804 |
Hormone Sensitive Women (HS+) | 0.0174 | -0.0114 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS- by examining threat attention bias assessed during the visual dot-probe paradigm.~The Visual Dot-Probe Paradigm asks participants to detect a target stimulus that is embedded in a matrix of distracting stimuli (e.g., a target stimulus, an angry face, might be embedded in a matrix of neutral distractor faces). Attention biases are inferred from faster response times to detect a threatening stimulus in a matrix of neutral stimuli relative to response time to detect neutral stimuli in neutral matrices. Thus, positive times reflect attention bias toward threat, whereas negative times reflect attention bias away from threat." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | attention bias in milliseconds (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 36.92 | -42.35 |
Hormone Sensitive Women (HS+) | -0.57 | -9.04 |
5 reviews available for melatonin and Hypergonadotropic Hypogonadism
Article | Year |
---|---|
The evidence for seasonal variations of testosterone in men.
Topics: Body Mass Index; Circadian Rhythm; Humans; Hypogonadism; Male; Melatonin; Motor Activity; Seasons; S | 2013 |
[Hormone therapy in the aging male. Estrogen, DHEA, melatonin, somatotropin].
Topics: Aged; Aged, 80 and over; Aging; Dehydroepiandrosterone; Estrogens; Growth Hormone; Hormone Replaceme | 2004 |
Sex, steroids, and sleep: a review.
Topics: Animals; Depressive Disorder; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Hyp | 1999 |
[Melatonin. I. Physiology of its secretion].
Topics: Alcoholism; Body Constitution; Circadian Rhythm; Cushing Syndrome; Electromagnetic Fields; Female; H | 2000 |
[Certain results and perspectives of the study of the role of the epiphysis in obstetrics and gynecology (literature survey)].
Topics: Female; Humans; Hypogonadism; Labor, Obstetric; Lactation; Melatonin; Menopause; Menstruation; Ovari | 1974 |
1 trial available for melatonin and Hypergonadotropic Hypogonadism
Article | Year |
---|---|
Abnormal melatonin secretion in hypogonadal men: the effect of testosterone treatment.
Topics: Adolescent; Adult; Follicle Stimulating Hormone; Humans; Hypogonadism; Klinefelter Syndrome; Luteini | 1997 |
22 other studies available for melatonin and Hypergonadotropic Hypogonadism
Article | Year |
---|---|
Melatonin appears to protect against steroidogenic collapse in both mice fed with high-fat diet and H
Topics: Animals; Cell Line; Cholesterol Side-Chain Cleavage Enzyme; Diet, High-Fat; Disease Models, Animal; | 2019 |
[Investigation, treatment and monitoring of late-onset hypogonadism in males: the official guidelines of the International Society for the Study of the Study of the Aging Male (ISSAM) with comments].
Topics: Aging; Androgens; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; France; Hormones; Human Gr | 2003 |
Altered melatonin secretion in hypogonadal men: clinical evidence.
Topics: Adolescent; Adult; Circadian Rhythm; Darkness; Follicle Stimulating Hormone; Humans; Hypogonadism; L | 2005 |
Increased nocturnal melatonin secretion in male patients with hypogonadotropic hypogonadism and delayed puberty.
Topics: Activity Cycles; Adolescent; Cohort Studies; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1995 |
The antigonadotrophic effect of melatonin in Syrian hamsters is modulated by prostaglandin.
Topics: Animals; Brain Chemistry; Circadian Rhythm; Cricetinae; Dinoprostone; Drug Administration Schedule; | 1994 |
Daytime plasma melatonin levels in male hypogonadism.
Topics: Adult; Chorionic Gonadotropin; Circadian Rhythm; Dehydroepiandrosterone; Dehydroepiandrosterone Sulf | 1996 |
Testosterone treatment alters melatonin concentrations in male patients with gonadotropin-releasing hormone deficiency.
Topics: Adolescent; Adult; Estradiol; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; | 1996 |
Nocturnal secretory patterns of melatonin, luteinizing hormone, prolactin and cortisol in male patients with gonadotropin-releasing hormone deficiency.
Topics: Adolescent; Adult; Circadian Rhythm; Gonadotropins; Humans; Hydrocortisone; Hypogonadism; Luteinizin | 1996 |
Abnormal melatonin secretion in male patients with hypogonadism.
Topics: Adolescent; Adult; Circadian Rhythm; Darkness; Estradiol; Follicle Stimulating Hormone; Gonadotropin | 1996 |
Early morning melatonin levels in hypogonadal men.
Topics: Circadian Rhythm; Gonadal Steroid Hormones; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; H | 1996 |
Hypogonadotrophic hypogonadism and primary amenorrhoea associated with increased melatonin secretion from a cystic pineal lesion.
Topics: Adolescent; Amenorrhea; Brain Diseases; Cysts; Female; Gonadotropins, Pituitary; Humans; Hypogonadis | 1996 |
Pulsatile patterns of melatonin secretion in patients with gonadotropin-releasing hormone deficiency: effects of testosterone treatment.
Topics: Adolescent; Adult; Case-Control Studies; Gonadotropin-Releasing Hormone; Humans; Hypogonadism; Lutei | 1997 |
Melatonin concentration before and during testosterone replacement in primary hypogonadic men.
Topics: Adult; Circadian Rhythm; Humans; Hypogonadism; Male; Melatonin; Reference Values; Testosterone | 1997 |
Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men.
Topics: Adolescent; Adult; Body Temperature; Circadian Rhythm; Hormones; Humans; Hypogonadism; Leuprolide; M | 1997 |
Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men.
Topics: Adolescent; Adult; Body Temperature; Circadian Rhythm; Hormones; Humans; Hypogonadism; Leuprolide; M | 1997 |
Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men.
Topics: Adolescent; Adult; Body Temperature; Circadian Rhythm; Hormones; Humans; Hypogonadism; Leuprolide; M | 1997 |
Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men.
Topics: Adolescent; Adult; Body Temperature; Circadian Rhythm; Hormones; Humans; Hypogonadism; Leuprolide; M | 1997 |
Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men.
Topics: Adolescent; Adult; Body Temperature; Circadian Rhythm; Hormones; Humans; Hypogonadism; Leuprolide; M | 1997 |
Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men.
Topics: Adolescent; Adult; Body Temperature; Circadian Rhythm; Hormones; Humans; Hypogonadism; Leuprolide; M | 1997 |
Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men.
Topics: Adolescent; Adult; Body Temperature; Circadian Rhythm; Hormones; Humans; Hypogonadism; Leuprolide; M | 1997 |
Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men.
Topics: Adolescent; Adult; Body Temperature; Circadian Rhythm; Hormones; Humans; Hypogonadism; Leuprolide; M | 1997 |
Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men.
Topics: Adolescent; Adult; Body Temperature; Circadian Rhythm; Hormones; Humans; Hypogonadism; Leuprolide; M | 1997 |
Effects of testosterone treatment on plasma melatonin levels in male hypogonadism.
Topics: Female; Humans; Hypogonadism; Male; Melatonin; Testosterone | 1998 |
Elevated nocturnal melatonin is a consequence of gonadotropin-releasing hormone deficiency in women with hypothalamic amenorrhea.
Topics: Adult; Amenorrhea; Circadian Rhythm; Cluster Analysis; Female; Follicle Stimulating Hormone; Gonadot | 1998 |
The association between melatonin and sleep stages in normal adults and hypogonadal men.
Topics: Adolescent; Adult; Hormone Replacement Therapy; Humans; Hypogonadism; Male; Melatonin; Sleep Stages; | 1999 |
Melatonin hypersecretion in male patients with adult-onset idiopathic hypogonadotropic hypogonadism.
Topics: Adult; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hypogonadism; Luteinizi | 2000 |
Brief report: melatonin-related hypogonadotropic hypogonadism.
Topics: Adult; Chorionic Gonadotropin; Follicle Stimulating Hormone; Gonadotropins, Pituitary; Humans; Hypog | 1992 |
Melatonin--the hormone of darkness.
Topics: Adolescent; Adult; Aged; Animals; Calcinosis; Child; Child, Preschool; Female; Humans; Hypogonadism; | 1992 |
Rapid decrease in melatonin production during successful treatment of delayed puberty.
Topics: Adolescent; Ethinyl Estradiol; Female; Humans; Hypogonadism; Melatonin; Puberty, Delayed; Specimen H | 1989 |
Non-Cartesian pineal function.
Topics: Animals; Female; Gonadotropins; Humans; Hypogonadism; Luteinizing Hormone; Male; Melatonin; Olfactio | 1971 |